Evaluating Surgical and Integrative Oncology Options in Early-Stage Breast Carcinoma with Favorable Histology and Multiple Lesions

A Case-Based Review of Attributable Benefit, Attributable Risk, and the Role of Integrative Strategies Alongside Definitive Treatment

Yoon Hang Kim, MD, MPH  •  Board-Certified in Preventive Medicine  |  Integrative & Functional Medicine Physician

Introduction

When a client presents with a new diagnosis of early-stage breast carcinoma, two sets of questions emerge almost simultaneously. The first is clinical: what are the treatment options, what does each accomplish, and what happens if treatment is declined? The second is personal: what else can I do, and is there anything beyond standard treatment that the evidence supports?

Both questions deserve direct, evidence-grounded answers. This article uses a composite clinical scenario — drawn from common presentations and publicly available literature, with no individual client information — to walk through both. It evaluates the surgical options and their attributable benefit, examines what happens without surgery, and then reviews the integrative oncology landscape: what has evidence, what does not, and where the line falls between complement and alternative.

Composite Clinical Scenario

The following scenario is a teaching composite. It does not represent any individual client. 

A premenopausal woman presents with recently diagnosed early-stage (stage I) breast cancer. Imaging identifies multiple breast lesions. Biopsy reveals invasive carcinoma; tubular carcinoma is among the histologic types discussed, though final classification awaits definitive surgical pathology. A separate area of atypical ductal hyperplasia (ADH) is identified. The tumor is hormone-receptor-positive (ER+/PR+) and HER2-negative, with a Ki-67 in the low-to-borderline range. Staging workup shows nonspecific pulmonary nodules with no evidence of metastatic disease. The client is interested in understanding both conventional and integrative approaches.

Part I: Evaluating Surgical Options

The surgical decision: lumpectomy versus mastectomy in multifocal or multicentric disease

For a single early-stage tumor, breast-conserving surgery (lumpectomy) plus radiation is equivalent to mastectomy for survival — this was established by the NSABP B-06 trial at 20-year follow-up, which showed essentially identical disease-free, distant-disease-free, and overall survival between the two approaches [1]. With multiple lesions, the conversation shifts. The critical variable is whether the lesions are in the same quadrant (multifocal) or different quadrants (multicentric). Multifocal disease can sometimes be managed with wider excision if clear margins and acceptable cosmesis are achievable. Multicentric disease generally favors mastectomy, because achieving clear margins across widely separated sites is difficult and local recurrence rates rise [2].

For favorable histologies — pure tubular carcinoma (≥90% tubular architecture, low/intermediate grade, HER2-negative) — the NCCN guidelines provide a distinct management pathway. If purity criteria are met, endocrine therapy is the principal adjuvant consideration, with no role for chemotherapy in node-negative disease [2]. If any lesion is reclassified as invasive ductal carcinoma of no special type (NST) on final pathology, the management algorithm changes and genomic assays may become relevant.

Attributable benefit of surgery: what can and cannot be calculated

No clinical trial has ever compared surgery to observation for invasive breast cancer, and for ethical reasons none ever will. Surgery is the foundational curative modality, established by inference from natural-history data rather than from randomized attributable-risk arithmetic. What can be said: with modern multimodal treatment, breast-cancer-specific survival for early-stage ER-positive disease approaches 100%. Every adjuvant modality that follows surgery trims a residual risk that surgery has already made very small.

The attributable risk of omitting surgery

Because the question of surgical omission arises frequently in integrative oncology practice — particularly when clients are evaluating alternative approaches — the evidence deserves direct examination across three tiers.

Tier 1 — Historical natural history. In the Middlesex Hospital series (Bloom, 1805–1933) and Johnstone’s actuarial reanalysis, median survival from symptom onset in untreated breast cancer was 2.7 years, with 5- and 10-year survival of approximately 18% and 4% [3,4]. These were symptomatic, mostly locally advanced cancers in the pre-screening era and represent the ceiling of harm. Approximately 5–10% of untreated women survived beyond 10 years, disproportionately those with lower-grade tumors. Natural-history data specific to untreated tubular carcinoma do not exist.

Tier 2 — Modern untreated cohorts. In a SEER analysis of clients who received no surgery, radiation, or chemotherapy, median progression time in ER-positive disease was approximately 4.2 years from stage I to II, 2 years from II to III, and 0.9 years from III to IV [5]. The pattern is unmistakable: untreated early ER-positive disease advances slowly but essentially without exception, and tempo accelerates at each stage. In a premenopausal client with decades of remaining life expectancy, slow pace is not protective.

Tier 3 — Randomized data on surgical omission. The only trials comparing surgery to primary endocrine therapy alone enrolled women aged ≥70. A Cochrane meta-analysis found overall survival HR 0.86 (95% CI 0.73–1.00) for surgery plus endocrine therapy versus endocrine therapy alone — little or no overall survival difference — but progression-free survival strongly favored surgery (HR 0.65), and local control was markedly inferior without it (HR 0.28) [6,7]. The apparent OS equivalence exists because competing mortality in elderly populations censors the endpoint. In a premenopausal client, that competing-mortality shield does not exist, and an unresected tumor has decades in which to progress to metastatic, incurable disease.

Synthesis. Even conservatively, omitting surgery converts a condition whose breast-cancer-specific survival approaches 100% into one where local progression is near-certain within roughly five to ten years and lifetime metastatic conversion is probable. The attributable harm plausibly runs 30–60 or more absolute percentage points of lifetime breast-cancer mortality — one to two orders of magnitude larger than the benefit of any adjuvant or integrative modality. With multiple lesions, the risk is amplified. Surgery is where the curative work happens.

Ancillary surgical considerations

Sentinel lymph-node biopsy provides staging information that governs downstream systemic therapy decisions. Its value is information, not direct cure. For pure tubular carcinoma, the likelihood of positive nodes is low — a meta-analysis of 680 patients from 20 studies found overall axillary involvement of approximately 13%, with substantially lower rates in tumors under 1 cm [8]. Lymphedema risk is approximately 5% with sentinel-node biopsy versus ~20% with full axillary dissection.

Nonspecific pulmonary nodules are found incidentally in roughly 25–50% of chest CT scans and are overwhelmingly benign. In the absence of other findings suggestive of distant spread, they do not change the surgical plan. Follow-up imaging per Fleischner Society criteria is standard [9].

Atypical ductal hyperplasia (ADH) requires excisional clarification before the surgical plan is finalized. ADH carries an upgrade rate to DCIS or invasive carcinoma at excision of roughly 10–30%, with MRI-detected lesions trending toward the higher end. An upgrade can alter margin planning and shift the lumpectomy-versus-mastectomy decision.

Part II: Integrative Oncology Strategies Alongside Definitive Treatment

The recommendation in this scenario is unambiguous: definitive surgical treatment first. Additional treatment steps (radiation, endocrine therapy) are determined after final surgical pathology. The question that follows — what else can I do? — is legitimate and answerable, provided the distinction between integrative and alternative is maintained. Integrative oncology uses evidence-based complementary therapies alongside conventional treatment. Alternative oncology uses unproven approaches instead of it. The Society for Integrative Oncology (SIO) and ASCO have jointly published guidelines endorsing specific integrative therapies for symptom management during breast cancer treatment [10,11]. Neither organization endorses any alternative therapy as a substitute for standard care.

Therapies with guideline-level evidence for symptom management

The SIO–ASCO breast cancer guideline (2017, ASCO-endorsed 2018) evaluated more than 80 therapies and graded them by strength of evidence. Moderate-to-strong recommendations include meditation and mindfulness-based stress reduction, yoga, acupuncture, massage therapy, and music therapy for various symptom domains (anxiety, depression, fatigue, pain, quality of life) [10,11]. American ginseng received support for cancer-related fatigue in the 2024 guideline update [12]. The MSK About Herbs database (www.aboutherbs.com) provides evidence-based drug-interaction data for approximately 290 supplements and should be consulted before any supplement is taken alongside prescribed oncologic therapy [13,14].

Modified citrus pectin (PectaSol)

Modified citrus pectin (MCP) inhibits galectin-3, a carbohydrate-binding protein implicated in cancer cell adhesion, aggregation, immune evasion, and metastasis [15]. A prospective phase II study of 59 men with non-metastatic biochemically relapsed prostate cancer found that PectaSol-MCP improved PSA doubling time over six months [16]. PectaSol-C has demonstrated synergy with paclitaxel in ovarian cancer models via galectin-3/STAT3 targeting [17]. The NCI cancer drug dictionary lists MCP as having potential antioxidant, immunostimulatory, and anti-metastatic activities. MCP has a favorable safety profile with no significant documented drug interactions. It is one of the more scientifically grounded integrative supplements and is reasonable to discuss as a supportive adjunct alongside standard treatment.

Medicinal mushrooms

Turkey tail (Trametes versicolor) is the most extensively researched medicinal mushroom in oncology. Its active compounds — polysaccharide-K (PSK) and polysaccharopeptide (PSP) — are immunomodulators approved in Japan as adjunctive cancer treatment since the mid-1970s. A phase I dose-escalation trial at the University of Minnesota and Bastyr University tested 3, 6, and 9 g/day of a Trametes versicolor preparation and found that up to 9 g/day was safe and well tolerated in women with breast cancer after completing radiotherapy, with dose-related trends toward improved immune markers (increased lymphocyte counts, NK cell activity, CD8+ T cells, CD19+ B cells) at higher doses [18]. A meta-analysis of 23 RCTs found PSK safe when combined with chemotherapy, with survival benefits reported in gastric and colorectal cancer [19,20]. Reishi, shiitake, and maitake have promising preclinical data but more limited clinical evidence. A 2023 systematic review of medicinal mushroom supplements in cancer identified survival benefits specifically for PSK in gastric cancer and Huaier granules in hepatocellular and breast cancer [20].

Intravenous vitamin C

A randomized phase 2 trial (Bodeker et al., Redox Biology, 2024) showed that adding high-dose IV vitamin C (pharmacological ascorbate) to standard chemotherapy doubled median overall survival in metastatic pancreatic cancer from 8.3 to 16 months, with improved quality of life and no increase in adverse events [21]. This is the strongest RCT-level evidence for IV vitamin C in any cancer type. The critical framing: it was an adjunct to chemotherapy in metastatic disease, not a replacement for standard treatment in an early-stage, curable setting.

The Berkson ALA/LDN protocol

Dr. Burton Berkson published case series combining IV alpha-lipoic acid with oral low-dose naltrexone (LDN) in advanced cancers. Four pancreatic cancer cases across two publications showed prolonged survival or complete metabolic response on PET [22,23]. A hepatocellular carcinoma case showed complete disappearance of liver lesions after 27 months [24]. The total published case count is fewer than ten. Case series have no control group, are subject to publication bias, and represent the weakest form of clinical evidence. They are hypothesis-generating, not efficacy-establishing.

Ivermectin and mebendazole

The strongest human data point is a single randomized trial of 40 clients with metastatic colorectal cancer, where mebendazole added to standard chemotherapy showed improved response rate and PFS [25]. A phase I/II trial of ivermectin combined with immunotherapy in metastatic triple-negative breast cancer was presented at ASCO 2025. Neither agent has been studied in early-stage, hormone-receptor-positive breast cancer. The circulated “Makis protocol” doses substantially exceed anything studied in humans, and the protocol’s own co-authors publicly disagree about its safety. A detailed informational review is available at www.ifmsynergy.com [26].

Part III: The Evidence Hierarchy

Surgery (foundational; not calculable from RCT data, plausibly 30–60+ absolute points of lifetime mortality avoided) > Guideline-endorsed integrative therapies (acupuncture, meditation, yoga — for symptom management) > PectaSol and turkey tail mushroom (plausible mechanism, phase I–II human data, favorable safety) > IV vitamin C and ALA/LDN (developing evidence as adjuncts in advanced disease; not tested in early-stage breast cancer) > Ivermectin/mebendazole (minimal human oncology evidence; no application to this clinical scenario).

The most consequential decision is not which supplement to take — it is whether to proceed with curative surgery. Every integrative strategy discussed in this article is most valuable when layered on top of definitive treatment, not used in place of it. The right time to introduce integrative approaches is after the surgical plan is finalized, in coordination with the treating oncology team.

Recommended Resources

For clients and practitioners seeking a comprehensive, evidence-based guide to integrative oncology strategies alongside conventional treatment: Integrative Oncology: Evidence-Based Strategies to Support Cancer Treatment by Yoon Hang Kim, MD, MPH (available at www.directintegrativecare.com and major retailers including Kobo). Additional recommended reading includes Radical Remission by Kelly A. Turner, PhD (HarperOne, 2014); Love, Medicine and Miracles by Bernie S. Siegel, MD (Harper & Row, 1986); and How to Starve Cancer by Jane McLelland (Agenor Publishing, 2018). Each contains genuine insight; each should be read as a complement to, not a substitute for, evidence-based treatment.

Important: This article is for educational purposes and does not constitute medical advice. The clinical scenario is a teaching composite and does not represent any individual client. Absolute benefit estimates for favorable-histology breast carcinoma are extrapolated from proportional risk reductions in higher-risk trial populations. Where trial data do not exist, that absence is stated. No intervention described here is recommended as a substitute for standard cancer treatment.

References

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–1241. PMID: 12393820.

2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Breast Cancer, v6.2026 (favorable-histology pathway, BINV-11). NCCN.org.

3. Bloom HJG, Richardson WW, Harries EJ. Natural history of untreated breast cancer (1805–1933): comparison of untreated and treated cases according to histological grade of malignancy. Br Med J. 1962;2(5299):213–221. PMID: 13870135.

4. Johnstone PA, Norton MS, Riffenburgh RH. Survival of patients with untreated breast cancer. J Surg Oncol. 2000;73:273–277.

5. Wu J, Liu H, Hu T, Long M, Zhou X, Wang S. The natural history of breast cancer: a chronological analysis of breast cancer progression using data from the SEER database. Ann Transl Med. 2022;10(6):365. doi:10.21037/atm-22-918. PMC9011255.

6. Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer. 2007;96(7):1025–1029. PMID: 17285133.

7. Morgan J, Wyld L, Collins KA, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2014;(5):CD004272.pub3. PMID: 35658165.

8. Papadatos G, Rangan AM, Psarianos T, Ung O, Taylor R, Boyages J. Probability of axillary node involvement in patients with tubular carcinoma of the breast. Br J Surg. 2001;88(6):860–864. PMID: 11412259.

9. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228–243. PMID: 28240562.

10. Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol. 2018;36(25):2647–2655. PMID: 29889605.

11. Greenlee H, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232.

12. Bower JE, Lacchetti C, Alici Y, et al. Management of fatigue in adult survivors of cancer: ASCO–Society for Integrative Oncology guideline update. J Clin Oncol. 2024;42(20):2456–2487. PMID: 38754041.

13. MSK Integrative Medicine Service. About Herbs, Botanicals & Other Products. www.aboutherbs.com.

14. Hou YN, Deng G, Mao JJ. Practical application of “About Herbs” website. Cancer J. 2019;25(5):357–366.

15. Eliaz I, Raz A. Pleiotropic effects of modified citrus pectin. Nutrients. 2019;11(11):2619.

16. Keizman D, Frenkel M, Peer A, et al. Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: results of a prospective phase II study. Nutrients. 2021;13(12):4295. PMID: 34959847. PMC8706421.

17. Hossein G, et al. PectaSol-C modified citrus pectin targets galectin-3-induced STAT3 activation and synergizes paclitaxel cytotoxic effect on ovarian cancer spheroids. Cancer Med. 2019;8(9):4315–4329.

18. Torkelson CJ, Sweet E, Martzen MR, Sasagawa M, Wenner CA, Gay J, Putiri A, Standish LJ. Phase 1 clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncol. 2012;2012:251632. PMC3369477.

19. Fritz H, et al. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review. Integr Cancer Ther. 2015;14(3):201–211.

20. Steele ML, et al. Medicinal mushroom supplements in cancer: a systematic review of clinical studies. Curr Oncol Rep. 2023;25(6):569–587.

21. Bodeker KL, Smith BJ, Berg DJ, et al. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biol. 2024;77:103375. PMID: 39369582. PMC11491967.

22. Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous α-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006;5(1):83–89. PMID: 16484716.

23. Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther. 2009;8(4):416–422. PMID: 20042414.

24. Berkson BM, et al. A review of the integrative treatment approach using IV ALA/LDN and long-term survival of a woman with hepatocellular carcinoma. Clinics in Oncology. 2020.

25. Hegazy SK, El-Azab GA, Zakaria F, Mostafa MF, El-Ghoneimy RA. Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. Life Sci. 2022;299:120536. PMID: 35385794.

26. Kim YH. The “Makis Protocol”: An Informational Review. ifmsynergy.com. August 2026.

27. Kim YH. Berkson’s ALA/LDN Protocol in Integrative Oncology. ifmsynergy.com. January 2026.

28. Kim YH. Evidence-based supplements for cholesterol management (includes MCP/PectaSol section). ifmsynergy.com. April 2026.

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with more than 20 years of clinical experience in integrative and preventive medicine. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with UCLA medical acupuncture certification. He specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. He is the author of 3 books and more than 20 articles.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com